Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAG vaccine (Sarah Cannon Research Institute)
- Development stage
- Discontinued
- Lead developer
- Gradalis
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**TAG vaccine** is an individualized, irradiated autologous whole-tumor-cell cancer vaccine genetically modified ex vivo with a nonviral plasmid encoding granulocyte-macrophage colony-stimulating factor and a transforming growth factor beta 2 antisense sequence. The product is intended to present each patient's broad tumor-antigen repertoire while locally increasing GM-CSF-mediated antigen presentation and reducing TGF-β2-mediated immunosuppression. It was evaluated in a Phase 1 study in patients with advanced metastatic carcinoma, with intradermal monthly administration after manufacture from resected tumor tissue. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21208907/))
- Other names
- Auto TAGTAGTGFβ2 antisense-GM-CSF gene-modified autologous tumor cell vaccineTGFB2-antisense-GMCSF gene-modified autologous tumor cell vaccineTGFB-2-antisense-GMCSF gene-modified autologous tumor cell vaccineTGFB 2-antisense-GMCSF gene-modified autologous tumor cell vaccineTriad vaccine
Beyond the preview
Go deeper on TAG vaccine (Sarah Cannon Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAG vaccine (Sarah Cannon Research Institute).